{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:48:39Z","timestamp":1793933319722,"version":"4.8.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Governmental Funding of Clinical Research within the National Health Service Sweden","award":["ALF young researcher Ida Skarping"],"award-info":[{"award-number":["ALF young researcher Ida Skarping"]}]},{"name":"the Governmental Funding of Clinical Research within the National Health Service Sweden","award":["ALF young researcher Looket Dihge"],"award-info":[{"award-number":["ALF young researcher Looket Dihge"]}]},{"name":"the Stig and Ragna Gorthon Foundation"},{"DOI":"10.13039\/501100003252","name":"Lunds Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009780","name":"Region Sk\u00e5ne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007436","name":"Familjen Erling-Perssons Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007436","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vetenskapsr\u00e5det [Swedish Research Council] (Sweden) (external review),"},{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Surgical sentinel lymph node biopsy (SLNB) is routinely used to reliably stage axillary lymph nodes in early breast cancer (BC). However, SLNB may be associated with postoperative arm morbidities. For most patients with BC undergoing SLNB, the findings are benign, and the procedure is currently questioned. A decision-support tool for the prediction of benign sentinel lymph nodes based on preoperatively available data has been developed using artificial neural network modelling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective geographical and temporal validation study of the noninvasive lymph node staging (NILS) model, based on preoperatively available data from 586 women consecutively diagnosed with primary BC at two sites. Ten preoperative clinicopathological characteristics from each patient were entered into the web-based calculator, and the probability of benign lymph nodes was predicted. The performance of the NILS model was assessed in terms of discrimination with the area under the receiver operating characteristic curve (AUC) and calibration, that is, comparison of the observed and predicted event rates of benign axillary nodal status (N0) using calibration slope and intercept. The primary endpoint was axillary nodal status (discrimination, benign [N0] vs. metastatic axillary nodal status [N+]) determined by the NILS model compared to nodal status by definitive pathology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean age of the women in the cohort was 65\u00a0years, and most of them (93%) had luminal cancers. Approximately three-fourths of the patients had no metastases in SLNB (N0 74% and 73%, respectively). The AUC for the predicted probabilities for the whole cohort was 0.6741 (95% confidence interval: 0.6255\u20130.7227). More than one in four patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009151, 26%) were identified as candidates for SLNB omission when applying the predefined cut-off for lymph node-negative\u00a0status from the development cohort. The NILS model showed the best calibration in patients with a predicted high probability of healthy axilla.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The performance of the NILS model was satisfactory. In approximately every fourth patient, SLNB could potentially be omitted. Considering the shift from postoperatively to preoperatively available predictors in this validation study, we have demonstrated the robustness of the NILS model. The clinical usability of the web interface will be evaluated before its clinical implementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Registered in the ISRCTN registry with study ID ISRCTN14341750.<\/jats:p>\n                    <jats:p>Date of registration 23\/11\/2018.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-024-11854-1","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T04:02:34Z","timestamp":1705377754000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Retrospective validation study of an artificial neural network-based preoperative decision-support tool for noninvasive lymph node staging (NILS) in women with primary breast cancer (ISRCTN14341750)"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1265-8649","authenticated-orcid":false,"given":"Ida","family":"Skarping","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3241-1109","authenticated-orcid":false,"given":"Julia","family":"Ellbrant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7932-3982","authenticated-orcid":false,"given":"Looket","family":"Dihge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1145-4297","authenticated-orcid":false,"given":"Mattias","family":"Ohlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8597-9224","authenticated-orcid":false,"given":"Linnea","family":"Huss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8862-1845","authenticated-orcid":false,"given":"P\u00e4r-Ola","family":"Bendahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7515-3130","authenticated-orcid":false,"given":"Lisa","family":"Ryd\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"key":"11854_CR1","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/annonc\/mdx308","volume":"28","author":"G Curigliano","year":"2017","unstructured":"Curigliano G, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017;28:1700\u201312. https:\/\/doi.org\/10.1093\/annonc\/mdx308.","journal-title":"Ann Oncol"},{"key":"11854_CR2","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1200\/JCO.21.00934","volume":"39","author":"M Brackstone","year":"2021","unstructured":"Brackstone M, et al. Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline. J Clin Oncol. 2021;39:3056\u201382. https:\/\/doi.org\/10.1200\/JCO.21.00934.","journal-title":"J Clin Oncol"},{"key":"11854_CR3","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s10549-021-06194-8","volume":"187","author":"S Keelan","year":"2021","unstructured":"Keelan S, et al. Breast cancer patients with a negative axillary ultrasound may have clinically significant nodal metastasis. Breast Cancer Res Treat. 2021;187:303\u201310. https:\/\/doi.org\/10.1007\/s10549-021-06194-8.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"11854_CR4","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/bjs.9401","volume":"101","author":"H Sackey","year":"2014","unstructured":"Sackey H, et al. Arm lymphoedema after axillary surgery in women with invasive breast cancer. J Br Surg. 2014;101(4):390\u20137. https:\/\/doi.org\/10.1002\/bjs.9401.","journal-title":"J Br Surg"},{"issue":"13","key":"11854_CR5","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1001\/jama.2013.277804","volume":"310","author":"R Rao","year":"2013","unstructured":"Rao R, Euhus D, Mayo HG, Balch C. Axillary node interventions in breast cancer: a systematic review. JAMA. 2013;310(13):1385\u201394. https:\/\/doi.org\/10.1001\/jama.2013.277804.","journal-title":"JAMA"},{"key":"11854_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-017-3361-y","volume":"17","author":"J de Boniface","year":"2017","unstructured":"de Boniface J, et al. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial. BMC cancer. 2017;17:1\u20137. https:\/\/doi.org\/10.1186\/s12885-017-3361-y.","journal-title":"BMC cancer"},{"key":"11854_CR7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1055\/s-0042-122853","volume":"77","author":"T Reimer","year":"2017","unstructured":"Reimer T, et al. Restricted axillary staging in clinically and sonographically node-negative early invasive breast cancer (c\/iT1\u20132) in the context of breast conserving therapy: first results following commencement of the Intergroup-Sentinel-Mamma (INSEMA) trial. Geburtshilfe und Frauenheilkunde. 2017;77:149\u201357. https:\/\/doi.org\/10.1055\/s-0042-122853.","journal-title":"Geburtshilfe und Frauenheilkunde"},{"key":"11854_CR8","first-page":"2080","volume":"39","author":"C De Cicco","year":"1998","unstructured":"De Cicco C, et al. Lymphoscintigraphy and radioguided biopsy of the sentinel axillary node in breast cancer. J Nucl Med. 1998;39:2080\u20134.","journal-title":"J Nucl Med"},{"key":"11854_CR9","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S1470-2045(10)70207-2","volume":"11","author":"DN Krag","year":"2010","unstructured":"Krag DN, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927\u201333. https:\/\/doi.org\/10.1016\/S1470-2045(10)70207-2.","journal-title":"Lancet Oncol"},{"key":"11854_CR10","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1001\/jama.2011.90","volume":"305","author":"AE Giuliano","year":"2011","unstructured":"Giuliano AE, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569\u201375. https:\/\/doi.org\/10.1001\/jama.2011.90.","journal-title":"JAMA"},{"key":"11854_CR11","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017;318:918\u201326. https:\/\/doi.org\/10.1001\/jama.2017.11470.","journal-title":"JAMA"},{"key":"11854_CR12","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S1470-2045(07)70278-4","volume":"8","author":"DN Krag","year":"2007","unstructured":"Krag DN, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8:881\u20138. https:\/\/doi.org\/10.1016\/S1470-2045(07)70278-4.","journal-title":"Lancet Oncol"},{"key":"11854_CR13","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1007\/s00268-012-1623-z","volume":"36","author":"S Pesek","year":"2012","unstructured":"Pesek S, Ashikaga T, Krag LE, Krag D. The false-negative rate of sentinel node biopsy in patients with breast cancer: a meta-analysis. World J Surgery. 2012;36:2239\u201351. https:\/\/doi.org\/10.1007\/s00268-012-1623-z.","journal-title":"World J Surgery"},{"issue":"5","key":"11854_CR14","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.breast.2012.06.013","volume":"21","author":"O Gentilini","year":"2012","unstructured":"Gentilini O, Veronesi U. Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: Sentinel node vs Observation after axillary UltraSouND). Breast. 2012;21(5):678\u201381. https:\/\/doi.org\/10.1016\/j.breast.2012.06.013.","journal-title":"Breast"},{"issue":"1","key":"11854_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.breast.2012.06.013","volume":"17","author":"LM van Roozendaal","year":"2017","unstructured":"van Roozendaal LM, et al. Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013\u201308). BMC Cancer. 2017;17(1):1\u20138. https:\/\/doi.org\/10.1016\/j.breast.2012.06.013.","journal-title":"BMC Cancer"},{"key":"11854_CR16","doi-asserted-by":"publisher","first-page":"101756","DOI":"10.1016\/j.eclinm.2022.101756","volume":"55","author":"T Reimer","year":"2023","unstructured":"Reimer T, et al. Patient-reported outcomes for the Intergroup Sentinel Mamma study (INSEMA): A randomised trial with persistent impact of axillary surgery on arm and breast symptoms in patients with early breast cancer. EClinicalMedicine. 2023;55:101756. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101756.","journal-title":"EClinicalMedicine"},{"key":"11854_CR17","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/bjs.10986","volume":"105","author":"SR Tee","year":"2018","unstructured":"Tee SR, et al. Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer. J Br Surg. 2018;105:1541\u201352. https:\/\/doi.org\/10.1002\/bjs.10986.","journal-title":"J Br Surg"},{"key":"11854_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-019-5827-6","volume":"19","author":"L Dihge","year":"2019","unstructured":"Dihge L, Ohlsson M, Ed\u00e9n P, Bendahl PO, Ryd\u00e9n L. Artificial neural network models to predict nodal status in clinically node-negative breast cancer. BMC Cancer. 2019;19:1\u20132. https:\/\/doi.org\/10.1186\/s12885-019-5827-6.","journal-title":"BMC Cancer"},{"key":"11854_CR19","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s10549-022-06636-x","volume":"194","author":"I Skarping","year":"2022","unstructured":"Skarping I, et al. The implementation of a noninvasive lymph node staging (NILS) preoperative prediction model is cost effective in primary breast cancer. Breast Cancer Res Treat. 2022;194:577\u201386. https:\/\/doi.org\/10.1007\/s10549-022-06636-x.","journal-title":"Breast Cancer Res Treat"},{"key":"11854_CR20","doi-asserted-by":"publisher","first-page":"1102254","DOI":"10.3389\/fonc.2023.1102254","volume":"13","author":"L Dihge","year":"2023","unstructured":"Dihge L, et al. The implementation of NILS: A web-based artificial neural network decision support tool for noninvasive lymph node staging in breast cancer. Front Oncol. 2023;13:1102254. https:\/\/doi.org\/10.3389\/fonc.2023.1102254.","journal-title":"Front Oncol"},{"key":"11854_CR21","doi-asserted-by":"publisher","unstructured":"Skarping, I. et al. The NILS Study Protocol: A Retrospective Validation Study of an Artificial Neural Network Based Preoperative Decision-Making Tool for Noninvasive Lymph Node Staging in Women with Primary Breast Cancer (ISRCTN14341750). Diagnostics (Basel) 12 (2022). https:\/\/doi.org\/10.3390\/diagnostics12030582","DOI":"10.3390\/diagnostics12030582"},{"key":"11854_CR22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ypmed.2007.08.012","volume":"45","author":"E von Elm","year":"2007","unstructured":"von Elm E, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Prev Med. 2007;45:247\u201351. https:\/\/doi.org\/10.1016\/j.ypmed.2007.08.012.","journal-title":"Prev Med"},{"key":"11854_CR23","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s12889-019-6846-6","volume":"19","author":"L Lofgren","year":"2019","unstructured":"Lofgren L, et al. Steering group of the National Register for Breast Cancer Validation of data quality in the Swedish National Register for Breast Cancer. BMC Public Health. 2019;19:495.","journal-title":"BMC Public Health"},{"key":"11854_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, et al. Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377\u201381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010.","journal-title":"J Biomed Inform"},{"key":"11854_CR25","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12916-019-1466-7","volume":"17","author":"B Van Calster","year":"2019","unstructured":"Van Calster B, et al. Calibration: the Achilles heel of predictive analytics. BMC Med. 2019;17:230. https:\/\/doi.org\/10.1186\/s12916-019-1466-7.","journal-title":"BMC Med"},{"key":"11854_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s41512-019-0064-7","volume":"3","author":"AJ Vickers","year":"2019","unstructured":"Vickers AJ, van Calster B, Steyerberg EW. A simple, step-by-step guide to interpreting decision curve analysis. Diagn progn Res. 2019;3:18. https:\/\/doi.org\/10.1186\/s41512-019-0064-7.","journal-title":"Diagn progn Res"},{"key":"11854_CR27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s41512-017-0012-3","volume":"1","author":"PC Austin","year":"2017","unstructured":"Austin PC, et al. Validation of prediction models: examining temporal and geographic stability of baseline risk and estimated covariate effects. Diagno Progn Res. 2017;1:12. https:\/\/doi.org\/10.1186\/s41512-017-0012-3.","journal-title":"Diagno Progn Res"},{"key":"11854_CR28","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1136\/bmj.b605","volume":"28","author":"DG Altman","year":"2009","unstructured":"Altman DG, Vergouwe Y, Royston P, Moons KG. Prognosis and prognostic research: validating a prognostic model. BMJ. 2009;28:338. https:\/\/doi.org\/10.1136\/bmj.b605.","journal-title":"BMJ"},{"key":"11854_CR29","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1186\/s41512-019-0060-y","volume":"98","author":"KG Moons","year":"2012","unstructured":"Moons KG, et al. Risk prediction models: II External validation, model updating, and impact assessment. Heart. 2012;98:691\u20138. https:\/\/doi.org\/10.1186\/s41512-019-0060-y.","journal-title":"Heart"},{"key":"11854_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41512-019-0060-y","volume":"3","author":"LE Cowley","year":"2019","unstructured":"Cowley LE, Farewell DM, Maguire S, Kemp AM. Methodological standards for the development and evaluation of clinical prediction rules: a review of the literature. Diagn Progn Res. 2019;3:1\u201323. https:\/\/doi.org\/10.1186\/s41512-019-0060-y.","journal-title":"Diagn Progn Res"},{"key":"11854_CR31","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1186\/s41512-019-0060-y","volume":"25","author":"JL Bevilacqua","year":"2007","unstructured":"Bevilacqua JL, et al. Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation. J Clin Oncol. 2007;25:3670\u20139. https:\/\/doi.org\/10.1186\/s41512-019-0060-y.","journal-title":"J Clin Oncol"},{"key":"11854_CR32","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.ejca.2012.04.025","volume":"49","author":"RF van la Parra","year":"2013","unstructured":"van la Parra RF. Assessment of the Memorial Sloan-Kettering Cancer Center nomogram to predict sentinel lymph node metastases in a Dutch breast cancer population. Eur J Cancer. 2013;49:564\u201371. https:\/\/doi.org\/10.1016\/j.ejca.2012.04.025.","journal-title":"Eur J Cancer"},{"key":"11854_CR33","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1186\/s12885-017-3535-7","volume":"17","author":"K Chen","year":"2017","unstructured":"Chen K, Liu J, Li S, Jacobs L. Development of nomograms to predict axillary lymph node status in breast cancer patients. BMC cancer. 2017;17:561. https:\/\/doi.org\/10.1186\/s12885-017-3535-7.","journal-title":"BMC cancer"},{"key":"11854_CR34","unstructured":"Fredriksson, I. \u00c5rsrapport 2021 fr\u00e5n Nationellt Kvalitetsregister f\u00f6r Br\u00f6stcancer (NKBC). (Cancercentrum, https:\/\/cancercentrum.se\/contentassets\/c36b580a94ab4c3794aa9d41bb954871\/ett-urval-av-data-fran-nkbc-rapporten-for2021.pdf, 2021)."},{"key":"11854_CR35","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3322\/caac.21754","volume":"72","author":"AN Giaquinto","year":"2022","unstructured":"Giaquinto AN, et al. Breast Cancer Statistics, 2022. CA Cancer J Clin. 2022;72:524\u201341. https:\/\/doi.org\/10.3322\/caac.21754.","journal-title":"CA Cancer J Clin"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-11854-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-11854-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-11854-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T04:04:38Z","timestamp":1705377878000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-11854-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["11854"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-11854-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2686975\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,16]]},"assertion":[{"value":"13 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This study was approved by the Swedish Ethical Review Authority (Ethical Review Board, Stockholm Department 3 Medicine, committee reference number: 2021\u201300174). Patients received study information through advertisements in the local press. By using the provided contact information, the patients were allowed to opt out. The ethics committee (Ethical Review Board, Stockholm Department 3 Medicine, committee reference number: 2021\u201300174) waived the requirement for informed consent and consent for publication. By law, all patients receiving treatment for BC at hospitals are consenting to register in a national registry of cancer. The local department for personal data admission at the hospital (KVB Samr\u00e5d, Region Sk\u00e5ne, Sweden) granted researchers access, with digital logging, to patients\u2019 digital medical charts. Only authorized users from the principal investigator had access to the NILS web calculator.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}